Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback